menu
    • menu
    [{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"MEDSIR","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Preclinical","graph3":"MEDSIR","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEDSIR \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"MEDSIR \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"MEDSIR","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ MEDSIR","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ MEDSIR"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Debiopharm","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Debiopharm"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Preclinical","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Repare Therapeutics \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Debio 0123

    Menu

    Debio 0123

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Debiopharm

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Debiopharm

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Debio 0123,Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : MEDSIR

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MEDSIR & Debiopharm Begin WIN-B Trial in Breast Cancer

                            Details : Debio 0123 is an oral, potent, highly selective, and brain-penetrant WEE1 inhibitor is being evaluated with trodelvy for HR-positive/HER2-negative triple negative breast neoplasms.

                            Product Name : Debio 0123

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 25, 2025

                            Lead Product(s) : Debio 0123,Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : MEDSIR

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Debiopharm

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Debiopharm

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Debio 0123

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Debiopharm Expands WEE1 Inhibitor Research in Gynecological and Biomarker-Driven Tumors

                            Details : Debio 0123, an oral, potent, highly selective, and brain-penetrant WEE1 inhibitor is being evaluated in Phase I clinical trial studies for patients with advanced solid tumors.

                            Product Name : Debio 0123

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 03, 2024

                            Lead Product(s) : Debio 0123

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MEDSIR

                            Spain arrow
                            AACR Annual meeting
                            Not Confirmed

                            MEDSIR

                            Spain arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Debio 0123,Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MEDSIR & Debiopharm Explore Synergy of Debio 0123 & Sacituzumab in Breast Cancer

                            Details : The collaboration aims to evaluate the safety and efficacy of Debio 0123, Debiopharm's investigational, potential best-in-class WEE1 inhibitor, together with Trodelvy (sacituzumab govitecan).

                            Product Name : Debio 0123

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 28, 2024

                            Lead Product(s) : Debio 0123,Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Repare Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Repare Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lunresertib,Debio 0123

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Debiopharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Repare and Debiopharm Dosed First Patient in Phase 1/1b MYTHIC Trial

                            Details : RP-6306 (lunresertib), an oral PKMYT1 inhibitor, is being developed in combination with Debio 0123, a selective WEE1 kinase inhibitor, for treating advanced solid tumors.

                            Product Name : RP-6306

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 30, 2024

                            Lead Product(s) : Lunresertib,Debio 0123

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Debiopharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Repare Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Repare Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Debio 0123,Lunresertib

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Debiopharm Partners with Repare To Explore PKMYT1 and WEE1 Inhibition

                            Details : This collaboration will explore synergy between Debio 0123, a selective WEE1 inhibitor, and RP-6306 (lunresertib), a first-in-class small molecule with anticancer activity.

                            Product Name : Debio 0123

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 01, 2024

                            Lead Product(s) : Debio 0123,Lunresertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Debiopharm

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Debiopharm

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Debio 0123,Carboplatin,Etoposide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Debiopharm Launches Phase 1 Research in Small Cell Lung Cancer with Wee1 Inhibitor Debio 0123 to Outsmart DDR

                            Details : Debio 0123 is a brain-penetrant, highly selective WEE1 kinase inhibitor combines with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC).

                            Product Name : Debio 0123

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 30, 2023

                            Lead Product(s) : Debio 0123,Carboplatin,Etoposide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Debiopharm

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Debiopharm

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Debio 0123,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Debiopharm Launches Phase 1/2 Combination Trial Investigating Brain-Penetrant Selective WEE1 Inhibitor for Bra...

                            Details : Debio 0123 is a brain-penetrant and highly selective WEE1 inhibitor, it is being investigated in combination with temozolomide (TMZ) in patients with recurrent or progressive glioblastoma and in combination with TMZ/RT (SOC) in newly diagnosed patients.

                            Product Name : Debio 0123

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 17, 2023

                            Lead Product(s) : Debio 0123,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Debiopharm

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Debiopharm

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Debio 0123

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Debiopharm Further Explores the Potential of its Potent, Highly Selective WEE1 Inhibitor Debio 0123 In Phase 1...

                            Details : Dose escalation, monotherapy trial launched to access the safety and preliminary anti-tumor activity of Debio 0123 in the treatment of advanced solid tumors.

                            Product Name : Debio 0123

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 16, 2021

                            Lead Product(s) : Debio 0123

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Debiopharm

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Debiopharm

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Debio 0123

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor

                            Details : Debio 0123 starts first-in-human, dose escalation phase I clinical trial assessing the safety and efficacy of the compound in combination with carboplatin to treat refractory solid tumors.

                            Product Name : Debio 0123

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 03, 2020

                            Lead Product(s) : Debio 0123

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth